AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04370392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal local anaesthetic instillation
Description: intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
Study NCT04028128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa group
Description: Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
Study NCT01592032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin antimicrobial-lock solution
Description: Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study NCT01592032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin antimicrobial-lock solution
Description: Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study NCT04028128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
Study NCT04503889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular electrical vagal nerve stimulation
Description: transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
Study NCT01592032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid antimicrobial-lock solution
Description: Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study NCT01592032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin antimicrobial-lock solution
Description: Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study NCT01592032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline antimicrobial-lock solution
Description: Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
Study NCT02733900 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: femoral head removal
Study NCT02733900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral head removal
Study NCT04503889 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular electrical vagal nerve stimulation
Description: transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
Study NCT02248870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
Study NCT02248870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
Study NCT04484285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: vagal nerve stimulation
Study NCT01682460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears Lubricant Eye Drops (Allergan)
Description: Eye drops QID for 1 month
Study NCT03347500 — intervention group
Intervention type: OTHER
Intervention: use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
Study NCT02370212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Study NCT02370212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02370212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Study NCT02370212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High intensity interval training
Study NCT01820728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3801 Injection
Study NCT01820728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F®
Study NCT05131295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
Study NCT05131295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Hydroxide Gel
Description: Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
Study NCT04525404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (heart, brain, lungs, liver)
Description: MRI (heart, brain, lungs, liver)
Study NCT04525404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bloodwork
Description: Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
Study NCT04525404 — intervention group
Intervention type: OTHER
Intervention: Cognitive testing
Description: NIH toolbox Cognitive Measures
Study NCT04525404 — intervention group
Intervention type: OTHER
Intervention: Olfaction testing
Description: Brief Smell Identification Test (BSIT)
Study NCT04525404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
Study NCT04525404 — intervention group
Intervention type: OTHER
Intervention: Walk Test
Description: Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
Study NCT03312556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
Study NCT03312556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill or patch. Single dose
Study NCT02345031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUT00063
Description: 600 mg, orally, once a day, for 4 weeks
Study NCT02345031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally, once a day, for 4 weeks
Study NCT04503889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS sham
Description: ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
Study NCT04503889 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS sham
Description: ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
Study NCT00859469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV infusion for 90 minutes
Study NCT01753531 — intervention group
Intervention type: DEVICE
Intervention: Flu Symptoms
Study NCT00736619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
Description: All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored.
Study NCT02903576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection of hESC-RPE in suspension
Description: The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
Study NCT02903576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection hESC-RPE seeded in a substrate
Description: Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
Study NCT02577081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT scan (CT scan)
Description: all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
Study NCT01309919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD
Description: Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
Study NCT01309919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diary
Description: Subjects will keep a bleeding diary for three months
Study NCT01309919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary
Description: Subjects will keep a bleeding diary for three months
Study NCT02287454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation program: REHACOP
Description: Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
Study NCT00729196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
Study NCT00729196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
Study NCT02477904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Dietary
Study NCT02477904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: Dietary
Study NCT01400269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
Description: Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
Study NCT05023954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis
Study NCT04147481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Abdominal Nerve Block with local anesthetics
Description: surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
Study NCT04147481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group Abdominal Nerve Block with saline
Description: surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
Study NCT00764855 — intervention group
Intervention type: PROCEDURE
Intervention: Automatic administration of propofol and opiates during routine clinical practice
Description: The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device.
Study NCT04161872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uricemin
Description: Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
Study NCT04161872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03586648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Multifocal
Description: TEST Lens
Study NCT03586648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A Sphere
Description: TEST Lens Sphere
Study NCT03586648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Multifocal
Description: CONTROL Lens
Study NCT03586648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Sphere
Description: CONTROL Lens Sphere
Study NCT04480112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology based social interactions
Description: Participants will be socially interacting using any available technology with members of the research team.
Study NCT02373475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional ventilation
Description: Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
Study NCT02373475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protective lung ventilation
Description: Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
Study NCT03655210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: HL151(1Tab) once a day for 4 weeks of treatments
Study NCT03655210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
Study NCT01702350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: Oral formulation of an an antibacterial
Study NCT03952910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online pain education program
Description: Online pain education program
Study NCT02501239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accept Yourself!
Study NCT02501239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Study NCT03273985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Trigger point deep dry needling
Study NCT03273985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Trigger point ischemic compression
Study NCT02025309 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular monitorisation
Study NCT02025309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitorisation
Study NCT02886975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low protein diet plus α-keto acid
Description: 0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
Study NCT04480112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No research related technology based social interactions
Description: No technology based social interactions with the research team.
Study NCT01880424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching Placebo Capsules, Oral, once daily
Study NCT01880424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide 290 ug Capsules, Oral, once daily
Study NCT03328754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerscope placed bilaterally for class II correction
Description: Powerscope placed bilaterally for class II correction
Study NCT03328754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2 Forsus
Description: Forsus placed bilaterally for class II correction
Study NCT02267395 — intervention group
Intervention type: OTHER
Intervention: (1) cranio-cervical flexion test;
Description: Test to determine level of strength for Deep Neck Flexor muscles
Study NCT02267395 — intervention group
Intervention type: OTHER
Intervention: (2) scapular dyskinesis test
Description: Test to determine scapular control
Study NCT02267395 — intervention group
Intervention type: OTHER
Intervention: (3) deep neck flexor endurance test.
Description: Test do determine endurance for the deep neck flexor muscle group.
Study NCT03616548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endoscopic surveillance
Description: Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
Study NCT01987648 — intervention group
Intervention type: PROCEDURE
Intervention: Elective Craniotomy Patients
Description: Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
Study NCT03754296 — intervention group
Intervention type: DEVICE
Intervention: CATCHVIEW
Description: Revascularization device
Study NCT01464203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT coronary angiography
Description: CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries.
Study NCT01464203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
Study NCT02790853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo brush biopsy and incisional biopsy
Study NCT02790853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo PS2.1/PS3 imaging
Study NCT02790853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy
Description: Undergo HRME imaging
Study NCT02790853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Applied on mucosa
Study NCT01187758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops and focus group meetings
Description: Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
Study NCT01983293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QLV based implant strategy
Study NCT01983293 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care implant strategy
Study NCT03581305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDOPA
Description: High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
Study NCT03581305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-DASB
Description: High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.